SOURCE: Nutra Pharma Corporation

Nutra Pharma Corporation

April 12, 2011 09:00 ET

Nutra Pharma Announces Nyloxin™ Distribution Through Innovatix

Nutra Pharma's Distributor, Nutritional Alliance, Has Established Contractual Relationships With Innovatix for the Distribution of Nyloxin™

CORAL SPRINGS, FL--(Marketwire - Apr 12, 2011) - Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that its Distributor, Nutritional Alliance, has established a contractual relationship with Innovatix for distribution of Nyloxin™ throughout the United States and particularly to the Long-Term Care and Senior Markets.

"This is a very important step for the Company," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "The aging population includes the primary users of narcotic pain drugs. These drugs can cause a range of side effects that may actually speed the decline of these patients. Nyloxin™ will allow seniors to greatly reduce their pain and inflammation without the subsequent loss of cognitive function. Innovatix is the right organization to market directly to this demographic and make a real difference in the lives of seniors," he explained.

Innovatix is the nation's largest non-acute care group purchasing organization (GPO). Launched in 1993, Innovatix provides high-quality group purchasing and consultative services to a national membership base of non-acute care pharmacy and institutional providers. Among others, their memberships include: Senior Living Providers, Continuing Care Retirement Communities (CCRCs), Assisted Living Facilities, Skilled Nursing Facilities, Independent Living Facilities, Memory Care Facilities and Hospices.

"We are excited to continue building our awareness platform for Nyloxin into various Healthcare sectors together with Innovatix. We expect for this continued relationship to flourish by not only increasing the visibility for Nyloxin but to help foster business growth in senior health care," commented Carlos Alfaras, Senior VP of Nutritional Alliance. "We believe that this will fundamentally change the way pain is treated in the senior community, allowing for healthier and more active seniors," he concluded.

Nyloxin™ is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin™ is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin™ is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit:

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The distribution of Nyloxin™ through Innovatix should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact Information

  • Contact:
    Nutra Pharma Corp.
    Nina Goldstein
    Email Contact